IBDEI1K6 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24909,2)
 ;;=^5002289
 ;;^UTILITY(U,$J,358.3,24910,0)
 ;;=D68.0^^107^1211^199
 ;;^UTILITY(U,$J,358.3,24910,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24910,1,3,0)
 ;;=3^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,24910,1,4,0)
 ;;=4^D68.0
 ;;^UTILITY(U,$J,358.3,24910,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,24911,0)
 ;;=C88.0^^107^1211^200
 ;;^UTILITY(U,$J,358.3,24911,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24911,1,3,0)
 ;;=3^Waldenstrom Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,24911,1,4,0)
 ;;=4^C88.0
 ;;^UTILITY(U,$J,358.3,24911,2)
 ;;=^5001748
 ;;^UTILITY(U,$J,358.3,24912,0)
 ;;=C91.02^^107^1211^3
 ;;^UTILITY(U,$J,358.3,24912,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24912,1,3,0)
 ;;=3^Acute Lymphoblastic Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,24912,1,4,0)
 ;;=4^C91.02
 ;;^UTILITY(U,$J,358.3,24912,2)
 ;;=^5001764
 ;;^UTILITY(U,$J,358.3,24913,0)
 ;;=C92.02^^107^1211^6
 ;;^UTILITY(U,$J,358.3,24913,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24913,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,24913,1,4,0)
 ;;=4^C92.02
 ;;^UTILITY(U,$J,358.3,24913,2)
 ;;=^5001791
 ;;^UTILITY(U,$J,358.3,24914,0)
 ;;=D09.3^^107^1211^46
 ;;^UTILITY(U,$J,358.3,24914,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24914,1,3,0)
 ;;=3^Carcinoma in Situ of Thyroid/Oth Endocrine Glands
 ;;^UTILITY(U,$J,358.3,24914,1,4,0)
 ;;=4^D09.3
 ;;^UTILITY(U,$J,358.3,24914,2)
 ;;=^5001955
 ;;^UTILITY(U,$J,358.3,24915,0)
 ;;=C22.0^^107^1211^87
 ;;^UTILITY(U,$J,358.3,24915,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24915,1,3,0)
 ;;=3^Hepatocellular Carcinoma
 ;;^UTILITY(U,$J,358.3,24915,1,4,0)
 ;;=4^C22.0
 ;;^UTILITY(U,$J,358.3,24915,2)
 ;;=^5000933
 ;;^UTILITY(U,$J,358.3,24916,0)
 ;;=C24.9^^107^1211^114
 ;;^UTILITY(U,$J,358.3,24916,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24916,1,3,0)
 ;;=3^Malig Neop Biliary Tract,Unspec
 ;;^UTILITY(U,$J,358.3,24916,1,4,0)
 ;;=4^C24.9
 ;;^UTILITY(U,$J,358.3,24916,2)
 ;;=^5000942
 ;;^UTILITY(U,$J,358.3,24917,0)
 ;;=C50.922^^107^1211^138
 ;;^UTILITY(U,$J,358.3,24917,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24917,1,3,0)
 ;;=3^Malig Neop Left Male Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,24917,1,4,0)
 ;;=4^C50.922
 ;;^UTILITY(U,$J,358.3,24917,2)
 ;;=^5133340
 ;;^UTILITY(U,$J,358.3,24918,0)
 ;;=C34.91^^107^1211^156
 ;;^UTILITY(U,$J,358.3,24918,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24918,1,3,0)
 ;;=3^Malig Neop Right Bronchus/Lung,Unspec Part
 ;;^UTILITY(U,$J,358.3,24918,1,4,0)
 ;;=4^C34.91
 ;;^UTILITY(U,$J,358.3,24918,2)
 ;;=^5000967
 ;;^UTILITY(U,$J,358.3,24919,0)
 ;;=C50.921^^107^1211^160
 ;;^UTILITY(U,$J,358.3,24919,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24919,1,3,0)
 ;;=3^Malig Neop Right Male Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,24919,1,4,0)
 ;;=4^C50.921
 ;;^UTILITY(U,$J,358.3,24919,2)
 ;;=^5001198
 ;;^UTILITY(U,$J,358.3,24920,0)
 ;;=C90.02^^107^1211^172
 ;;^UTILITY(U,$J,358.3,24920,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24920,1,3,0)
 ;;=3^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,24920,1,4,0)
 ;;=4^C90.02
 ;;^UTILITY(U,$J,358.3,24920,2)
 ;;=^5001753
 ;;^UTILITY(U,$J,358.3,24921,0)
 ;;=D51.9^^107^1211^25
 ;;^UTILITY(U,$J,358.3,24921,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24921,1,3,0)
 ;;=3^Anemia in Vitamin B12 Deficiency
 ;;^UTILITY(U,$J,358.3,24921,1,4,0)
 ;;=4^D51.9
 ;;^UTILITY(U,$J,358.3,24921,2)
 ;;=^5002289
